4.8 Article

Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis

期刊

CANCER RESEARCH
卷 70, 期 20, 页码 7764-7775

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-0471

关键词

-

类别

资金

  1. Associazione Italiana Ricerca sul Cancro
  2. Italian Ministry of Health

向作者/读者索取更多资源

Oncogene activation promotes an intrinsic inflammatory pathway that is crucial for cancer development. Here, we have investigated the actual effect of the inflammatory cytokine tumor necrosis factor (TNF) on the natural history of spontaneous mammary cancer in the HER2/neuT (NeuT) transgenic mouse model. Bone marrow transplantation from TNF knockout mice into NeuT recipients significantly impaired tumor growth, indicating that the source of TNF fostering tumor development was of bone marrow origin. We show that the absence of leukocyte-derived TNF disarranged the tumor vasculature, which lacked pericyte coverage and structural integrity, leading to diffuse vascular hemorrhage and stromal necrosis. In addition, tumor-associated Tie2-expressing monocytes were reduced and cytokine expression skewed from Th2 to Th1 type. Treatment of NeuT mice with anti-TNF antibody partially phenocopied the antitumor effect of TNF-deficient bone marrow cell transplantation, providing a strong preclinical background and rationale for the introduction of TNF antagonists in the treatment of human breast cancer, including basal-like samples for which consolidated targeted therapies do not exist. Cancer Res; 70(20); 7764-75. (C) 2010 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation

Milena Perrone, Claudia Chiodoni, Mara Lecchi, Laura Botti, Barbara Bassani, Annamaria Piva, Elena Jachetti, Matteo Milani, Daniele Lecis, Elda Tagliabue, Paolo Verderio, Sabina Sangaletti, Mario P. Colombo

Summary: Cancer can reprogram the bone marrow niche through the BM mesenchymal stem cells (MSC) and IL-1B/ATF3 signaling pathway, which promotes myeloid cell differentiation and tumor development. The expression of CD11b thorn population in the peripheral blood can be used as a potential biomarker for early diagnosis of breast cancer. This study suggests that targeting IL-1B or ATF3 may have therapeutic benefits for breast cancer patients.

CANCER RESEARCH (2023)

Article Oncology

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance

Vito Amodio, Simona Lamba, Rosaria Chila, Chiara M. Cattaneo, Benedetta Mussolin, Giorgio Corti, Giuseppe Rospo, Enrico Berrino, Claudio Tripodo, Federica Pisati, Alice Bartolini, Maria Costanza Aquilano, Silvia Marsoni, Gianluca Mauri, Caterina Marchio, Sergio Abrignani, Federica Di Nicolantonio, Giovanni Germano, Alberto Bardelli

Summary: Patients with DNA mismatch repair deficiency (MMRd) in colorectal cancer (CRC) often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. MMRp CRCs with variable fractions of MMRd cells may impact immune surveillance. Modulation of the MMRd fraction in MMR heterogeneous tumors can enhance their immunogenicity.

CANCER CELL (2023)

Correction Chemistry, Physical

Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer (dec, 10.1038/s43588-01431-x, 2022)

Emanuela Frittoli, Andrea Palamidessi, Fabio Iannelli, Federica Zanardi, Stefano Villa, Leonardo Barzaghi, Hind Abdo, Valeria Cancila, Galina V. Beznoussenko, Giulia Della Chiara, Massimiliano Pagani, Chiara Malinverno, Dipanjan Bhattacharya, Federica Pisati, Weimiao Yu, Viviana Galimberti, Giuseppina Bonizzi, Emanuele Martini, Alexander A. Mironov, Ubaldo Gioia, Flora Ascione, Qingsen Li, Kristina Havas, Serena Magni, Zeno Lavagnino, Fabrizio Andrea Pennacchio, Paolo Maiuri, Silvia Caponi, Maurizio Mattarelli, Sabata Martino, Fabrizio d'Adda di Fagagna, Chiara Rossi, Marco Lucioni, Richard Tancredi, Paolo Pedrazzoli, Andrea Vecchione, Cristiano Petrini, Francesco Ferrari, Chiara Lanzuolo, Giovanni Bertalot, Guilherme Nader, Marco Foiani, Matthieu Piel, Roberto Cerbino, Fabio Giavazzi, Claudio Tripodo, Giorgio Scita

NATURE MATERIALS (2023)

Article Oncology

Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement

Riccardo Ray Colciago, Irene Fischetti, Carlotta Giandini, Eliana La Rocca, Tiziana T. Rancati, Alicia Rejas Mateo, Mario Paolo Colombo, Laura Lozza, Claudia Chiodoni, Elena Jachetti, Maria Carmen De Santis

Summary: Oncological treatments are rapidly changing with the introduction of targeted anticancer drugs and regimens, and radioimmunotherapy is emerging as a promising field. This review provides an overview of the synergistic use of radiotherapy and immunotherapy and addresses important questions about its implementation, the patient selection criteria, and when it becomes standard clinical practice.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Article Gastroenterology & Hepatology

Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Rosaria M. Pipitone, Francesco Malvestiti, Grazia Pennisi, Oveis Jamialahmadi, Paola Dongiovanni, Giorgio Bertolazzi, Jussi Pihlajamaeki, Hannele Yki-Jaervinen, Umberto Vespasiani-Gentilucci, Federica Tavaglione, Samantha Maurotti, Cristiana Bianco, Gabriele Di Maria, Marco Enea, Anna L. Fracanzani, Vesa Kaerjae, Giulia Lupo, Ville Maennistoe, Marica Meroni, Roberto Piciotti, Sami Qadri, Rossella Zito, Antonio Craxi, Vito Di Marco, Calogero Camma, Claudio Tripodo, Luca Valenti, Stefano Romeo, Salvatore Petta, Stefania Grimaudo

Summary: The study found that the variation in the PDCD1 gene is associated with liver inflammation and progression to hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). The rs13023138 G>C variation was found to be associated with severe steatosis, NASH, and advanced fibrosis in individuals who underwent liver biopsy.

LIVER INTERNATIONAL (2023)

Article Cell Biology

SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence

Ubaldo Gioia, Sara Tavella, Pamela Martinez-Orellana, Giada Cicio, Andrea Colliva, Marta Ceccon, Matteo Cabrini, Ana C. Henriques, Valeria Fumagalli, Alessia Paldino, Ettore Presot, Sreejith Rajasekharan, Nicola Iacomino, Federica Pisati, Valentina Matti, Sara Sepe, Matilde I. Conte, Sara Barozzi, Zeno Lavagnino, Tea Carletti, Maria Concetta Volpe, Paola Cavalcante, Matteo Iannacone, Chiara Rampazzo, Rossana Bussani, Claudio Tripodo, Serena Zacchigna, Alessandro Marcello, Fabrizio d'Adda di Fagagna

Summary: SARS-CoV-2 causes DNA damage and alters the DNA damage response, leading to inflammation and cellular senescence.

NATURE CELL BIOLOGY (2023)

Article Oncology

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Caterina Cascini, Chiara Ratti, Laura Botti, Beatrice Parma, Valeria Cancila, Adriana Salvaggio, Cristina Meazza, Claudio Tripodo, Mario P. Colombo, Claudia Chiodoni

Summary: Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. In this study, it was found that intralesional administration of a TLR9 agonist can effectively inhibit tumor growth and also have therapeutic effects on untreated contralateral lesions. The findings suggest that TLR9 agonist can act as an in situ anti-tumor vaccine, activating innate and adaptive immune responses to suppress tumor growth.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Multidisciplinary Sciences

Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects

S. Cortellino, V. Quagliariello, G. Delfanti, O. Blazevits, C. Chiodoni, N. Maurea, A. Di Mauro, F. Tatangelo, F. Pisati, A. Shmahala, S. Lazzeri, V. Spagnolo, E. Visco, C. Tripodo, G. Casorati, P. Dellabona, V. D. Longo

Summary: This study explores the use of periodic cycles of a fasting-mimicking diet (FMD) to reduce the side effects caused by immunotherapy in cancer treatment. The combination of FMD cycles with immunotherapy shows promising results in delaying cancer growth and reducing cardiotoxicity.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth

Camilla Tombari, Alessandro Zannini, Rebecca Bertolio, Silvia Pedretti, Matteo Audano, Luca Triboli, Valeria Cancila, Davide Vacca, Manuel Caputo, Sara Donzelli, Ilaria Segatto, Simone Vodret, Silvano Piazza, Alessandra Rustighi, Fiamma Mantovani, Barbara Belletti, Gustavo Baldassarre, Giovanni Blandino, Claudio Tripodo, Silvio Bicciato, Nico Mitro, Giannino Del Sal

Summary: Mutant p53 stimulates serine/glycine synthesis and essential amino acid uptake to promote breast cancer growth. Under amino acid restriction, mutant p53 is stabilized and activates a transcriptional program that sustains a metabolic adaptive response promoting cancer cell proliferation.

NATURE COMMUNICATIONS (2023)

Meeting Abstract Oncology

Extracellular matrix drives high-grade breast cancer immune suppression down-modulating PD-1 on Treg cells via the IL-23/SATB1 axis

Giovanna Talarico, Mara Lecchi, Massimo Costanza, Claudia Chiodoni, Vera Cappelletti, Paolo Verderio, Massimo Di Nicola, Francesco Bertolini, Mario Paolo Colombo, Sabina Sangaletti

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations

Roberto Ferrara, Giuseppe Lo Russo, Chiara Maura Ciniselli, Annamaria Piva, Barbara Bassani, Elena Jachetti, Giuseppina Calareso, Valeria Duroni, Settimio Di Gregorio, Claudia Proto, Arsela Prelaj, Alessandro De Toma, Mario Occhipinti, Marta Brambilla, Sara Manglaviti, Laura Mazzeo, Arturo Rinaldi, Teresa Beninato, Monica Ganzinelli, Filippo De Braud, Marina Chiara Garassino, Paolo Verderio, Mario Paolo Colombo, Sabina Sangaletti

CANCER RESEARCH (2023)

Article Cell Biology

Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in β-thalassemia

Annamaria Aprile, Laura Raggi, Simona Bolamperti, Isabella Villa, Mariangela Storto, Gaia Morello, Sarah Marktel, Claudio Tripodo, Maria Domenica Cappellini, Irene Motta, Alessandro Rubinacci, Giuliana Ferrari

Summary: Clinical evidence suggests a relationship between blood and bone, but the underlying mechanism is not fully understood. A study using beta-thalassemia as a model found that increased fibroblast growth factor 23 (FGF23) levels in patients and mice with beta-thalassemia were induced by erythropoietin via ERK1/2 and STAT5 pathways. Inhibiting FGF23 signaling with carboxyl-terminal FGF23 peptide rescued bone defects and restored hematopoietic stem cell function in mice with beta-thalassemia. FGF23 may serve as a molecular link connecting anemia, bone, and the hematopoietic stem cell niche.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Meeting Abstract Gastroenterology & Hepatology

Programmedcell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Grazia Pennisi, Rosaria Maria Pipitone, Francesco Malvestiti, Oveis Jamialahmadi, Paola Dongiovanni, Giorgio Bertolazzi, Jussi Pihlajamaki, Hannele Yki-Jarvinen, Umberto Vespasiani Gentilucci, Federica Tavaglione, Samantha Maurotti, Cristiana Bianco, Gabriele Di Maria, Marco Enea, Anna Ludovica Fracanzani, Vesa Karja, Giulia Lupo, Ville Mannisto, Marica Meroni, Roberto Piciotti, Sami Qadri, Rossella Zito, Antonio Craxi, Vito Di Marco, Calogero Camma, Claudio Tripodo, Luca Valenti, Stefano Romeo, Salvatore Petta, Stefania Grimaudo

JOURNAL OF HEPATOLOGY (2023)

暂无数据